Detailed view for PF3D7_1470500

Basic information

TDR Targets ID: 3002
Plasmodium falciparum, phosphodiesterase delta, putative
Source Database / ID:  PlasmoDB   |   GeneDB   |   MPMP

pI: 6.9809 | Length (AA): 815 | MW (Da): 97169 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 6

Druggability Group : DG4

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00233   3'5'-cyclic nucleotide phosphodiesterase

Gene Ontology

Mouse over links to read term descriptions.
GO:0030552   cAMP binding  
GO:0009187   cyclic nucleotide metabolic process  
GO:0004114   3',5'-cyclic-nucleotide phosphodiesterase activity  
GO:0008081   phosphoric diester hydrolase activity  
GO:0007165   signal transduction  

Metabolic Pathways

Purine metabolism (KEGG)

Structural information

Modbase 3D models:

There are 6 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
381 788 1f0j (A) 161 507 23.00 0 1 0.49 -0.59
391 705 2h44 (A) 546 853 21.00 0 1 0.83 -1.68
329 710 4wzi (B) 230 654 17.00 0 1 0.753712 -0.64
376 709 3v93 (A) 280 608 21.00 0 1 0.748816 -0.78
399 710 3ecm (A) 493 819 25.00 0 1 0.695822 -0.72
403 759 1zkl (A) 155 455 28.00 0 0.99 0.603037 0.05

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile gametocyte, Female Gametocyte, Male Gametocyte. PlasmoDB Lasonder E
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile Sporozoite. Zanghi G
Upregulation Percent Ranking Stage Dataset
Lower 20-40% percentile intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, Oocyst, Ring. Otto TD Zanghi G
Upregulation Percent Ranking Stage Dataset
Lower 0-20% percentile intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs. Otto TD
Show/Hide expression data references
  • Otto TD New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq.
  • Lasonder E Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression.
  • PlasmoDB Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB
  • Zanghi G A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection.

Orthologs

Ortholog group members (OG5_155418)

Species Accession Gene Product
Plasmodium berghei PBANKA_1333700   phosphodiesterase delta
Plasmodium falciparum PF3D7_1470500   phosphodiesterase delta, putative
Plasmodium knowlesi PKNH_1210500   cyclic nucleotide phosphodiesterase, putative
Plasmodium vivax PVX_116945   cyclic nucleotide phosphodiesterase, putative
Plasmodium yoelii PY07430   calcium/calmodulin-stimulated cyclic nucleotide phosphodiesterase, putative
Plasmodium yoelii PY03619   Drosophila melanogaster GH21295p

Essentiality

No essentiality data collected for this gene and/or its orthologs.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Druggability index (range: 0 to 1): 0.5

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

  • Assay for Phosphodiesterase, 3' 5'-Cyclic Nucleotide Crude Complex (3.1.4.17 ) Sigma-Aldrich
  • Automatic link to known assays based on EC numbers.

Reagent availability

No reagent availability information for this target.

Bibliographic References

2 literature references were collected for this gene.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier PF3D7_1470500 (Plasmodium falciparum), phosphodiesterase delta, putative
Title for this comment
Comment